Immunology is being rewritten: why this matters for global equity investors

Schroders

Research

8 Pages

Schroders argues immunology’s $216 billion market is being reshaped by precision therapies, biologic-like pills, combination regimens, and early cell-therapy work. The piece frames the shift as more than incremental drug innovation: incumbents’ injection-led franchises face pricing and switching risk as new mechanisms raise efficacy expectations.

Key Takeaways

Market disruption: Immunology generates $216 billion annually, but oral, precision, combination, and cell therapies are reshaping incumbents’ pricing power.
Convenience matters: Schroders identifies five investor considerations, including whether pills can match injections and move earlier in treatment pathways.
Winners need breadth: Schroders highlights three winner traits: late-stage breadth, credible oral/combination strategies, and payer-aware commercial capabilities.
Source: IQVIA Forecast Link, Dec 2025; IQVIA Institute, Dec 2025.

Join our newsletter to have all of this content + Exclusive Newsletter Bonus Content delivered to your inbox every week

Related Content

Scroll to Top